From: Phase 1 study of intraventricular 131I-omburtamab targeting B7H3 (CD276)-expressing CNS malignancies
 | Ratios | T test |
---|---|---|
Dose 1 Sampling (n = 33) | ||
CSF (mGy/mCi) | 1.01 (0.46–4.6) |  |
Blood (mGy/mCi) | 0.04 (0.01–0.24) |  |
CSF/blood ratio | 24 (3–767) |  |
Dose 1 Scans (n = 23) | ||
Brain(mGy/mCi) | 1.16 (0.2–3.75) |  |
CSF (mGy/mCi) | 1.04 (0.25–2.84) |  |
Dose 2 Sampling | ||
 < 2220 MBq (n = 20) CSF | 0.89 (0.34–2.18) | 0.09* |
 > 2220 MBq (n = 13) | 1.37 (0.76–3.98) |  |
 < 2220 MBq (n = 20) CSF/blood ratio | 38.2 (4.8–59.3) | 0.02* |
 > 2220 MBq (n = 13) | 50.7 (14.9–314.2) |  |
 | Absorbed radiation dose (rads) |  |
Cumulative dose for all administrations | ||
CSF | 1672 (336.2–8966) |  |
Blood | 82 (15–236.9) |  |